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Background: Conventional methods of sweat testing are time consuming and have many steps that can and do lead to errors. This study compares
conventional sweat testing to a new quantitative method, the CF Quantum® (CFQT) sweat test. This study tests the diagnostic accuracy and
analytic validity of the CFQT.
Methods: Previously diagnosed CF patients and patients who required a sweat test for clinical indications were invited to have the CFQT test
performed. Both conventional sweat testing and the CFQT were performed bilaterally on the same day. Pairs of data from each test are plotted as a
correlation graph and Bland–Altman plot. Sensitivity and speciﬁcity were calculated as well as the means and coefﬁcient of variation by test and
by extremity. After completing the study, subjects or their parents were asked for their preference of the CFQT and conventional sweat testing.
Results: The correlation coefﬁcient between the CFQT and conventional sweat testing was 0.98 (95% conﬁdence interval: 0.97–0.99).
The sensitivity and speciﬁcity of the CFQT in diagnosing CF was 100% (95% conﬁdence interval: 94–100%) and 96% (95% conﬁdence interval:
89–99%), respectively. In one center in this three center multicenter study, there were higher sweat chloride values in patients with CF and also
more tests that were invalid due to discrepant values between the two extremities. The percentage of invalid tests was higher in the CFQT method
(16.5%) compared to conventional sweat testing (3.8%) (p b 0.001). In the post-test questionnaire, 88% of subjects/parents preferred the CFQT
test.
Conclusions: The CFQT is a fast and simple method of quantitative sweat chloride determination. This technology requires further reﬁnement to
improve the analytic accuracy at higher sweat chloride values and to decrease the number of invalid tests.
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The approved methods for sweat testing are Gibson-Cooke
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can result in quantity not sufficient (QNS) sweat test samples
exceeding 20% and thus, delays in diagnosis [2]. These methods
are time intensive and for parents of infants with an abnormal
newborn screening test for cystic fibrosis (CF), the parents may
need to wait for 60–90 minutes or more for results of the sweat
test. Therefore, there is a critical need to improve sweat testing
technology.
The CF Quantum® Sweat Test System (CFQT) is the next
generation evolution of the CF Indicator™ system originally
manufactured by Medtronic, Inc., Minneapolis, Minnesota [3].
This test has three components: (1) a portable, wearable electrodell rights reserved.
Fig. 1. Electrode and controller set on a child’s arm.
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a chloride test patch that collects the sweat (a visible chemical
reaction occurs in the patch that results in a white precipitate in the
center of the patch. The surface area of the white precipitate is
directly proportional to the sweat chloride value. Fig. 2); and (3) an
analyzer which scans the patch with a camera and calculates the
sweat chloride value.
In this multicenter pilot study, we performed bilateral con-
ventional sweat tests and bilateral CFQT tests in patients with
a previous diagnosis of CF or CF related metabolic syndrome
(CRMS [4]) and in patients who required a sweat test for clinical
indications. Our primary objective was to compare the diagnostic
accuracy and analytic validity of the CFQT to conventional sweat
testing. Secondary objectives were to compare the quantity not
sufficient (QNS) rates of the conventional and CFQT tests and to
determine the subjects’/parents’ preference of test systems.
2. Methods
Results are reported as per the recommendations of the
STARD (Standards for Reporting of Diagnostic Accuracy)Fig. 2. CFQT patches: on left, sweat chloride of 16 mmol/L; on righinitiative [5]. (STARD checklist and flow diagrams for analytic
validity and diagnostic accuracy are available in the online
supplement.) This study was completed at the University
of Wisconsin, Madison, WI, the University of Minnesota,
Minneapolis, MN and at the University of Utah, Salt Lake City,
UT (clinicaltrials.gov identifier NCT01345617). Institutional
review board approval was obtained at all three sites and all
subjects or legal guardians signed consent forms prior to
participation in the study. Patients with previously diagnosed
CF or CRMS (n = 88) were invited to undergo a conventional
sweat test and CFQT test during a routine clinic appointment.
The first test to be performed, CFQT or conventional sweat
testing, was randomly assigned in this group. We also invited
patients to participate in the study who had a sweat test ordered
by their provider (n = 82), either because of a clinical suspicion
of CF or as part of follow-up of an abnormal CF newborn
screening test. The subjects in this group had the conventional
sweat test performed first and the CFQT test performed second.
Each subject had a bilateral conventional sweat test performed
and a bilateral CFQT test performed on the same day. The
preferred site was the forearm. An area of the arm did not
undergo pilocarpine iontophoresis or collection of sweat more
than once. If there was inadequate space on the forearm for both
tests, then the CFQT was performed on the thighs. Subjects
were invited into the study based on investigator and research
coordinator availability and subjects’ willingness to sign the
consent form. Thus, patients were not studied consecutively.
Conventional sweat testing was performed per the standards
of the Clinical and Laboratory Standards Institute (CLSI) [6].
Sweat testing at the University of Wisconsin was by GCQPIT
with sweat collected on filter paper; sweat testing at the
University of Utah was by GCQPIT with collection of sweat on
gauze, and conventional sweat testing at the University of
Minnesota was by the Wescor Macroduct® Sweat Test system.
Pilocarpine iontophoresis occurred for 5 minutes and collection
of sweat occurred for 30 minutes. All three sites used the same
model of chloridometer: Labconco model 442-5000, Kansas
City, Missouri. Additionally, all three sites participated in
quality assurance through the College of American Pathologistst, sweat chloride of 83 mmol/L (as measured by CF analyzer).
Table 1
Characteristics of study subjects.
Known CF or CRMS Referred for sweat test
Total number 88 82
Center 1 28 28
Center 2 28 29
Center 3 32 25
Female gender — no. (%) 49 (56) 40 (49)
Center 1 14 (50) 14 (50)
Center 2 16 (57) 15 (52)
Center 3 19 (59) 11 (44)
Age
Mean ± SD (yr) 12.6 ± 5.5 7.8 ± 13.2
Center 1 14.7 ± 5.3 5.5 ± 12.7
Center 2 12.1 ± 5.3 10.3 ± 12.6
Center 3 11.2 ± 5.5 7.3 ± 14.4
Range 1–29 yrs 12 days–66 yrs
Center 1 7–29 yrs 12 days–53 yrs
Center 2 1–20 yrs 15 days–49 yrs
Center 3 1–19 yrs 24 days–66 yrs
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75 mg of sweat per the GCQPIT method and less than 15 μL
per the Wescor Macroduct® method. Sweat testing was per-
formed bilaterally and the results were not averaged.
For the CFQT, pilocarpine iontophoresis occurred for
8 minutes (this was the approved administration time of
iontophoresis for the CFQT controller and electrode set per
the United States Food and Drug Administration (FDA)). The
collection of sweat on the patch occurred until the sweat front
(a red circle on the patch) reached a stop ring of 15 mm in
diameter. In preclinical laboratory testing, this volume of sweat
correlated with a sweat rate exceeding 1 g/M2/minute. The test
was deemed QNS if the sweat front did not reach the stop ring
by 20 minutes. The sweat collection time was recorded on the
case report form. After obtaining an adequate amount of sweat,
the patch was removed from the extremity and allowed to
dry for a minimum of 15 minutes prior to being placed in the
analyzer.
For both the conventional sweat tests and the CFQT,
the test was considered invalid if the sweat chloride values
from the two extremities was N15 mmol/L difference for
sweat chlorides of N60 mmol/L and were considered invalid
for a difference of N10 mmol/L for sweat chloride values of
≤60 mmol/L [6].
At the Universities of Wisconsin and Minnesota, the clinical
laboratory technician performing the conventional sweat test
also performed the CFQT test. At the University of Utah, staff
from the clinical laboratory performed the conventional sweat
test and a research nurse performed the CFQT test.
The interpretation of sweat test results was per the United States
Cystic Fibrosis Foundation guidelines [7]. For infants less than
6 months of age, a sweat chloride of ≤29 mmol/L was normal,
30–59 mmol/Lwas intermediate, and≥60 mmol/Lwas abnormal
and consistent with CF. For subjects ≥6 months of age, a sweat
chloride of ≤39 mmol/L was normal, 40–59 was intermediate,
and ≥60 mmol/L was abnormal and consistent with CF. With
bilateral sweat testing being performed, the interpretation of the
results used the higher of the two sweat chloride values, as per the
CLSI guidelines [6].
After the conventional sweat test and CFQT tests were
performed, the subjects or their legal guardians completed a
questionnaire in which they stated their preference for one of
the tests (available in online supplement).
2.1. Statistical analysis
Conventional sweat test and CFQT test results were com-
pared using a scatter plot of matching pairs from the same
extremity. Individual data points were not graphed and compared if
one or both tests were insufficient due to either QNS or technical
difficulty or the test was invalid due to discrepant values from the
two extremities. The Pearson correlation coefficient and corre-
sponding 95% confidence intervals (CI) for the overall study and
each participating site were calculated. A Bland–Altman analysis
was conducted to examine the level of agreement between
results obtained by the CFQT and conventional sweat testing
[8]. Within-subject variability between tests was analyzed bycalculating the coefficient of variation for paired samples. The
95% confidence intervals for the coefficient of variations were
constructed using the nonparametric bootstrap method. Diagnostic
outcomes of the CFQT and conventional sweat test were evaluated
by calculating the Kappa statistic. Sensitivity and specificity of the
index test (CFQT) compared to the reference test (GCQPIT/
Macroduct®) were calculated with 95%CIs. The duration of sweat
collection time between conventional sweat testing and CFQT was
compared using a two-sample test. The proportions of QNS
and invalid tests were compared between the conventional
sweat tests and CFQT using a paired McNemar’s test. All
p-values were two-sided and p-values b0.05 were considered
statistically significant.
3. Results
The first subject to enter the study was in May 2012 and the
last subject to complete the study was in September 2013.
There were 57 subjects at the University of Wisconsin site (28
with a previously known diagnosis of CF or CRMS and 29
referred to the sweat testing laboratory); there were 56 subjects
at the University of Minnesota site (28 with previously diag-
nosed CF or CRMS and 28 referred to the sweat testing
laboratory), and there were 57 subjects at the University of
Utah site (32 with a previous diagnosis of CF or CRMS and 25
referred to the sweat test laboratory). The characteristics of the
subjects are shown in Table 1. Preliminary data have been
presented at the European Cystic Fibrosis Conference [9] and
the North American Cystic Fibrosis Conference [10].
Of the potential 340 bilateral conventional sweat tests, 4
tests were invalid (2 with discrepant sweat chloride values and
2 with sweat chloride values N160 mmol/L). Of the potential
340 bilateral CFQT tests, there were 40 that were unavailable
for analysis (2 tests had analyzer technical error, 4 tests were
invalid due to sweat chloride greater than 160 mmol/L [two
of these four were in the same patient with invalid GCQPIT
results of N160 mmol/L], 15 tests had smearing of sweat on the
patch [7 of these were sweat collections on the thigh], 18 tests
523M.J. Rock et al. / Journal of Cystic Fibrosis 13 (2014) 520–527had discrepant sweat chloride value results and 1 subject refused
the test on the second extremity).
The QNS rates were 2.6% for the conventional sweat test
(9 of 340 tests, 95% CI: 1.2–5.0%) and 4.7% for the CFQT test
(16 of 339 tests, 95% CI: 2.7–7.6%) (p = 0.046). When the
conventional sweat test was QNS, there was also a QNS in the
same subject for the CFQT in 8 of the 9 tests. For conventional
sweat testing, QNS occurred in 2 subjects who were b6 months
old and 4 subjects who were N6 months old. For the CFQT,
QNS occurred in 3 subjects who were b6 months old and 9
subjects who were N6 months old. Of note is that of the 64
CFQT tests that were performed on thighs, 6 of these (9%) were
QNS. There were 275 CFQT tests performed on the forearm
with 10 tests (3.6%) resulting in QNS (p = 0.092).
The overall tests that were not available (QNS plus invalid tests)
were 13 of 340 (3.8%; 95% CI: 2.2–6.4%) for conventional sweat
testing and 56 of 339 (16.5%; 95% CI: 13.0–20.8%) for CFQT
(p b 0.001). The unavailable test results by number of patients
were 8 subjects by conventional sweat testing (2 subjects were
b6 months of age and 6 subjects were N6 months of age) and 39
subjects by CFQT (12 subjects were b6 months of age and 27
subjects were N6 months of age). Most of these unavailable tests
were one of the two bilateral tests. Thus, sweat test interpretation
for at least one test was available for 154 of the 170 subjects (91%)
(Fig. 2 of online supplement).
The average collection time of sweat in the CFQT test was
8.8 ± 3.6 minutes. This was significantly less (p b 0.001) than
the standard 30 minute collection time for conventional sweat
testing.
After accounting for QNS sweat tests and invalid tests/technical
difficulties, there were 278 evaluable pairs of conventional sweat
tests and CFQT available for analysis The CFQT results plotted
against the conventional sweat test results are in Fig. 3. The overall
Pearson correlation coefficient was 0.98 (95% CI: 0.97–0.99) The
correlation coefficient did not vary between centers (0.99 at centers
1 and 2 and 097 at center 3). Bland–Altman plot of the differences
of the CFQT and conventional sweat test versus their averages is
illustrated in Fig. 4.
The coefficient of variation between paired extremities
values by test were CFQT: 5.5% (95% CI: 4.8–6.3%);
Macroduct®: 4.5% (95% CI: 3.5–5.5%); filter paper: 4.3%
(95% CI: 3.5–5.3%); and gauze: 3.8% (95% CI: 3.0–4.6%).
The coefficient of variation values for all tests was well below
10%, indicating acceptable within-subject variability between
tests.
There were 5 tests in 3 subjects (two previously known to have
CF) in which the conventional sweat test results were intermediate
but the CFQT results were in the definitively abnormal range.
(Table 2 shows interpretation of test data per subject with CFQT
as the index test and conventional sweat testing as the reference
test.) In a 15 yr old with CF, sweat chloride results per the
Macroduct® method were 55 and 54 mmol/L on the right and left
arms, respectively, with CFQT results of 67 and 65 mmol/L on
the right and left arms, respectively. In a 17 yr old with CF, sweat
chloride results per GCQPIT were 54 and 55 mmol/L on the right
and left arms, respectively, with CFQT results of 60 and 62 on the
right and left arms, respectively. Lastly, in a 40 day oldreferred to the laboratory due to an abnormal CF newborn
screen, the GCQPIT result on the right arm was 59 mmol/L
and the CFQT result on the right thigh was 62 mmol/L. Sweat
smeared the patch on the left thigh, thus there were no available
results for comparison on the left extremities. If we take a
conservative approach and state that these CFQT results were
false positives, then the CFQT sensitivity was 100% (95% CI: 94–
100%) and the specificity was 96% (95% CI: 89–99%). The
Kappa statistic was 96% (95% CI: 92–100%) indicating an
excellent level of agreement between the CFQT and conventional
sweat test results.
The conventional sweat testing procedures did not result in
any adverse events. In the CFQT tests, there was one subject
who had redness at the site of the pilocarpine iontophoresis that
lasted for several days and then self-resolved. In the post-test
questionnaire, 88% of subjects/parents preferred the CFQT test.
4. Discussion
This pilot study has demonstrated that the CFQT provides a
quantitative measure of sweat chloride values and yields results
that reliably distinguishes normal (non-CF) subjects from persons
with CF. This technology is easy to perform, yields results more
quickly than traditional sweat testing and is preferred by patients or
their parents over traditional sweat testing.
Although one can establish a diagnosis of cystic fibrosis
based on identifying two mutations, there are many mutations
that are of unknown consequence. This may be resolved some
day by the CFTR2 project [11], but currently, the vast majority
of mutations have not been definitively characterized. Addi-
tionally, the number of mutations that are on either newborn
screening panels or are available from commercial laboratories
varies. Guidelines from both the United States CF Foundation
[7] and the European Cystic Fibrosis Society [12] state that the
sweat test remains as the diagnostic test of choice to rule in or
rule out CF. Another advantage of the sweat test, compared to
genetic testing, is that results are available on the same day of
the test.
The original description of the sweat test was by Gibson and
Cooke in 1959 [13] and this technique has not appreciably
changed in the last 60 yrs. After stimulation of sweat glands by
iontophoresis of pilocarpine, sweat is collected on gauze or
filter paper. In the original 1959 description of the procedure,
sweat chloride analysis was by the polarographic method of
Zimmerman and Layton [14]. This utilized a reaction between
mercury and chloride in solution, and the measurement of
current at a fixed applied voltage was directly proportional to
the chloride concentration. (An alternative method of measur-
ing chloride is the Schales and Schales [15] titrimetric method
in which titration of the sweat sample with mercuric nitrate and
an indicator solution of s-diphenylcarbazone was performed
until an end point was reached of a pale violet color.) Chloride
determination later evolved to the coulometric titration method
of Cotlove [16]. This utilizes the principle of silver ions
generated from a silver anode combining with the chloride to
result in silver-chloride. A current is passed through the liquid
and as silver-chloride is formed, the current decreases which
Fig. 3. CFQT results against conventional sweat test results. Solid line, regression line. Shaded area, intermediate sweat chloride values.
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the silver concentration back to its original level prior to the
chloride induced precipitation. This process of generating fresh
silver ions continues until all the chloride is precipitated. The
concentration of chloride in the original solution is then
determined by measuring the length of time during which the
silver-generating current flowed.
An alternative method of sweat collection is by theMacroduct®
method [17,18] in which sweat is collected in microbore tubing.
For both the GCQPIT and Macroduct® methods, there are many
steps of pipetting reagents in order to prepare the sweat sample for
analysis in the chloridometer. (There is a new FDA approved
chloridometer, the Elitech Chlorochek® Chloridometer®, that can
accept a 10 μL sample of sweat directly from the microbore
tubing.) Thus, there many steps in the sweat testing procedure in
which errors can occur.
The three components of the CFQT yield a faster and
simpler procedure of quantitative sweat testing. The controller
and electrode set is a wearable device for iontophoresis of
pilocarpine into the skin. This uses a pilocarpine interface gel
similar to the pilogel that is used in the Macroduct® system.
Unlike the Macroduct® and GCQPIT methods in which thepatient is attached by wires to an external “box” that contains
batteries, the CFQT iontophoresis device is worn on an
extremity and the patient is not tethered to an external
battery-containing box (Fig. 1). The second component of the
CFQT is the chloride test patch. This contains a solution of
silver nitrate, a second solution of phenol red and potassium
chromate. As the sweat sample enters the fill port and migrates
to the front of the chloride test patch, it picks up the phenol red
and creates a dark red ring, which indicates the amount of sweat
that has been collected in the sample. When the chloride ions in
the sweat sample come into contact with the silver chromate of
the chloride test patch, an ion exchange reaction occurs. This ion
exchange creates silver chloride, an insoluble white precipitate
formed in the center of the patch. The third component of the
CFQT is the analyzer which uses a camera and computer software
to result in a sweat chloride value.
As can be seen in the Bland–Altman plot (Fig. 4), the
correlation between the CFQT and conventional sweat testing
was best at sweat chloride values of b80 mmol/L, with all of
the values within ±1.96 SD. There was more variation in sweat
chloride values above 80 mmol/L, particularly in center 3. This
site received a patch lot that was manufactured at a different
Fig. 4. Bland–Altman plot of differences between CFQT and conventional sweat chloride versus their average. Solid line, mean difference; dotted lines, mean
difference ± 1.96 SD.
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higher sweat chloride values in CFQT compared to GCQPIT in
this center still yields a diagnosis of CF, the analytical accuracy is
not as good as desired. The manufacturer of the CFQT recognizes
that the production of the patches needs to improve and that this
lot-to-lot variability needs to be eliminated. Similarly, the invalid
tests in the CFQT due to discrepancy in the bilateral values of
sweat chloride occurred exclusively in CF patients whose sweat
chloride values are in the higher range compared to normal
subjects. There were 3 subjects at center 1, 1 subject at center 2, andTable 2
GCQPIT/Macroduct versus CFQT results.
GCQPIT/Macroduct true diagnosis
CFQT results CF Non-CF
N (%) N (%) Total
Positive 72 (100%) 3 (4%) 75
Negative 0 (0%) 79 (96%) 79
Total 72 82 1545 subjects at center 3 who had invalid CFQT tests due to discrepant
bilateral sweat chloride values.
Despite the variability seen in the Bland–Altman plot, the
sensitivity and specificity of the CFQT is excellent. In the
results section of this paper, we used a conservative approach of
a specificity of 96% due to 5 tests in 3 subjects in which the
conventional sweat test results were intermediate but the CFQT
results were in the definitively abnormal range. In fact, two of
these subjects had a previous diagnosis of CF and the other
subject was a 40 day old with a positive newborn screen and
who was initially diagnosed with CRMS (F508del/I506L)
based on the GCQPIT result. A repeat GCQPIT at 5 months of
age had a definitively elevated sweat chloride values and this
baby’s diagnosis was changed to CF. Therefore, one would be
justified in stating that these were not false positive tests and
that the specificity of the CFQT is also 100%.
Another advantage of the CFQT system is that the collection
of sweat is much more rapid than conventional sweat testing
and thus the results are more quickly available (as soon as
15 minutes after the patch is removed). This aspect of this new
technology is particularly desirable in the arena of newborn
526 M.J. Rock et al. / Journal of Cystic Fibrosis 13 (2014) 520–527screening. Some laboratories will perform sweat collection in
the morning, but will not analyze sweat until the afternoon.
Previous research has shown that this delay in presenting sweat
test results to parents of infants with a positive newborn screen
can lead to misinformation and lingering concerns about CF in
their child [19].
A drawback of the CFQT is that in this pilot study, the
percentage of CFQT tests unavailable for analysis (16.5%) far
exceeded the percentage of conventional sweat tests unavail-
able for analysis (3.8%). The reasons for CFQT tests being
unavailable for analysis were technical errors, smearing of the
patches and invalid tests due to discrepant bilateral sweat
chloride values. Given that this was a pilot study of a new
technology, it is not surprising that there would be technical
issues with the equipment. With regard to the smearing of sweat
on the patches, there is a learning curve for technicians to
undergo and we have learned of a specific method in removing
the patches to prevent this smearing. Lastly, as discussed
previously, center 3 contributed the majority of discrepant
sweat chloride values due to their unique patch lot that yielded
higher sweat chloride values in CF patients.
Prior to beginning this study, we expected a lower QNS rate
with CFQT compared to conventional sweat testing. However,
there was no significant difference in the QNS rate of the CFQT
compared to conventional sweat testing. Of note is that the
protocol specified that for subjects who required a sweat test on
clinical grounds, the conventional sweat test was performed
first on the forearm. If there was inadequate space on the
forearm to also perform the CFQT test, then that test was
completed on the thigh. In comparing QNS rates of the CFQT
on the forearm compared to the thigh, there was a lower rate on
the forearm. In our personal experience with conventional
sweat testing, we have found that it is more challenging to
obtain a sufficient quantity of sweat from thighs compared to
forearms. A larger study that includes more infants would be
important to determine if this new technology yields a lower
QNS rate, an issue that is of high concern in newborn screening
programs [20]. Similarly, a larger study is required to establish
that this new method of quantitative sweat chloride determina-
tion is equivalent to the previously establish gold standard of
GCQPIT or Macroduct® [21].
In summary, the CFQT yields reliable sweat test results and
can distinguish patients with CF from normal subjects. The test
procedure is much faster than conventional sweat testing and
thus parents or patients can receive results in a timely fashion.
Further refinement of manufacturing processes of the patches
should yield results that show less variation.
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